Bottom line
How much do PHSYX and JDOC overlap?
64% of their top holdings overlap by weight. 15 securities appear in both funds' top 25, making up 71.9% of PHSYX's assets and 57.2% of JDOC's. They share a meaningful core but differ in the rest of the portfolio.
Updated Nov 22, 2026
Overlap at a glance
Holdings PHSYX and JDOC have in common
| Holding | % of PHSYX | % of JDOC | Overlap |
|---|---|---|---|
| Eli Lilly & Co. | 13.15% | 7.76% | 7.76% |
| Johnson & Johnson | 8.46% | 4.82% | 4.82% |
| UnitedHealth Group, Inc. | 6.93% | 5.85% | 5.85% |
| AbbVie, Inc. | 6.05% | 7.85% | 6.05% |
| Novartis AG | 5.13% | 1.60% | 1.60% |
| Merck & Co., Inc. | 4.88% | 4.82% | 4.82% |
| AstraZeneca plc | 4.67% | 3.76% | 3.76% |
| Thermo Fisher Scientific, Inc. | 4.50% | 3.73% | 3.73% |
| Intuitive Surgical, Inc. | 4.04% | 1.93% | 1.93% |
| Edwards Lifesciences Corp. | 2.80% | 1.73% | 1.73% |
| Roche Holding AG | 2.79% | 2.82% | 2.79% |
| CVS Health Corp. | 2.74% | 2.83% | 2.74% |
| Cardinal Health, Inc. | 2.12% | 1.51% | 1.51% |
| Novo Nordisk A/S | 1.90% | 2.61% | 1.90% |
| Bristol-Myers Squibb Co. | 1.75% | 3.57% | 1.75% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in PHSYX
- Sanofi SA — 3.23%
- Gilead Sciences, Inc. — 2.63%
- McKesson Corp. — 2.14%
- Vertex Pharmaceuticals, Inc. — 1.97%
- Boston Scientific Corp. — 1.80%
- Dexcom, Inc. — 1.64%
- Hoya Corp. — 1.52%
- Putnam Short Term Investment Fund — 1.35%
- HCA Healthcare, Inc. — 1.18%
- Amgen, Inc. — 1.11%
Only in JDOC
- Abbott Laboratories — 3.11%
- GSK plc — 2.47%
- Stryker Corp. — 2.23%
- Danaher Corp. — 2.16%
- Cencora, Inc. — 2.07%
- Argenx SE — 2.06%
- IQVIA Holdings, Inc. — 1.71%
- Teva Pharmaceutical Industries Ltd. — 1.60%
- Regeneron Pharmaceuticals, Inc. — 1.60%
- Biogen, Inc. — 1.56%
Asset mix
| Asset type | PHSYX | JDOC |
|---|---|---|
| Stocks | 98.2% | 99.2% |
| Other | 1.4% | — |
| Cash & short-term funds | 0.6% | — |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Country mix
| Country | PHSYX | JDOC |
|---|---|---|
| US | 76.2% | 75.2% |
| CH | 7.9% | 4.4% |
| GB | 6.4% | 6.2% |
| DK | 2.4% | 4.0% |
| FR | 3.2% | — |
| JP | 2.4% | 2.5% |
| NL | 1.2% | 2.4% |
| DE | — | 1.9% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Check another pair
FAQ
How much do PHSYX and JDOC overlap?
What stocks do PHSYX and JDOC have in common?
Should I own both PHSYX and JDOC?
Which holds more stocks, PHSYX or JDOC?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.